Goldstein E J, Citron D M
R. M. Alden Research Laboratory, Santa Monica Medical Center, California 90404.
J Clin Microbiol. 1988 Nov;26(11):2361-6. doi: 10.1128/jcm.26.11.2361-2366.1988.
The six species of the Bacteroides fragilis group are potent pathogens and commonly have different susceptibility patterns. We determined the relative annual isolation rate of anaerobic bacteria and the susceptibility of B. fragilis group species isolated during 1987 at two community hospitals. The relative frequencies of isolation of 261 strains were as follows: B. fragilis, 61%; B. thetaiotaomicron, 17%; B. distasonis, 7%; B. vulgatus, 6%; B. ovatus, 5%; and B. uniformis, 4%. A total of 234 recent clinical isolates were tested against cefmetazole, cefotetan, cefoxitin, ceftizoxime, clindamycin, imipenem, and piperacillin by a brucella agar dilution method. Imipenem was the most active agent tested with all but three isolates (two B. vulgatus and one B. distasonis) susceptible to less than 2 micrograms/ml. Of the cephalosporins tested, cefoxitin, cefotetan, and cefmetazole were relatively equal against B. fragilis, with 93 to 98% of strains susceptible to 32 micrograms/ml. Ceftizoxime was less active, with an MIC for 90% of strains tested of 128 micrograms/ml and only 75% of isolates susceptible to 32 micrograms/ml. Against B. ovatus, B. vulgatus, B. thetaiotaomicron, and B. uniformis, cefoxitin showed a two- to threefold-superior activity compared with that of cefotetan and cefmetazole. In general, ceftizoxime was much less active, except against B. distasonis, for which 78% of isolates were susceptible to 32 micrograms/ml compared with 68% for cefoxitin, 19% for cefmetazole, and 16% for cefotetan. Clindamycin and piperacillin showed activity similar to that of cefoxitin, except piperacillin was less active versus B. vulgatus and B. distasonis. We therefore suggest that clinical laboratories determine the species of B. fragilis group isolates as well as perform susceptibility studies on the isolates. Clinicians should be aware that while B. fragilis is the most frequent isolate, 38% of isolates are from other, more resistant B. fragilis group species.
脆弱拟杆菌群的六个菌种是强效病原体,通常具有不同的药敏模式。我们测定了两家社区医院1987年期间厌氧菌的相对年度分离率以及分离出的脆弱拟杆菌群菌种的药敏情况。261株菌株的相对分离频率如下:脆弱拟杆菌,61%;多形拟杆菌,17%;解脲拟杆菌,7%;普通拟杆菌,6%;卵形拟杆菌,5%;单形拟杆菌,4%。采用布鲁氏菌琼脂稀释法对总共234株近期临床分离株进行了头孢美唑、头孢替坦、头孢西丁、头孢唑肟、克林霉素、亚胺培南和哌拉西林的药敏试验。亚胺培南是受试药物中活性最强的,除三株分离株(两株普通拟杆菌和一株解脲拟杆菌)外,所有分离株对其的药敏浓度均低于2微克/毫升。在受试的头孢菌素中,头孢西丁、头孢替坦和头孢美唑对脆弱拟杆菌的活性相对相当,93%至98%的菌株对32微克/毫升的浓度敏感。头孢唑肟的活性较低,90%受试菌株的最低抑菌浓度为128微克/毫升,只有75%的分离株对32微克/毫升敏感。与头孢替坦和头孢美唑相比,头孢西丁对卵形拟杆菌、普通拟杆菌、多形拟杆菌和单形拟杆菌的活性高两至三倍。总体而言,头孢唑肟的活性要低得多,除了解脲拟杆菌,78%的解脲拟杆菌分离株对32微克/毫升敏感,而头孢西丁为68%,头孢美唑为19%,头孢替坦为16%。克林霉素和哌拉西林的活性与头孢西丁相似,只是哌拉西林对普通拟杆菌和解脲拟杆菌的活性较低。因此,我们建议临床实验室确定脆弱拟杆菌群分离株的菌种,并对分离株进行药敏研究。临床医生应意识到,虽然脆弱拟杆菌是最常见的分离株,但仍有38%的分离株来自其他耐药性更强的脆弱拟杆菌群菌种。